BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36974818)

  • 1. Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian Cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature.
    Chinczewski L; Feldhaus FW; Schmitt W; Braicu I; Roser E; Sehouli J
    Anticancer Res; 2023 Apr; 43(4):1655-1662. PubMed ID: 36974818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
    T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
    Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis.
    Vargas-Parra GM; González-Acosta M; Thompson BA; Gómez C; Fernández A; Dámaso E; Pons T; Morak M; Del Valle J; Iglesias S; Velasco À; Solanes A; Sanjuan X; Padilla N; de la Cruz X; Valencia A; Holinski-Feder E; Brunet J; Feliubadaló L; Lázaro C; Navarro M; Pineda M; Capellá G
    Int J Cancer; 2017 Oct; 141(7):1365-1380. PubMed ID: 28577310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: Complete response to pembrolizumab in a liver metastatic colon adenocarcinoma patient with a novel likely pathogenic germline MSH2 mutation.
    Xu Y; Li Q; Zhao J; Ni X; Li P; Hu W
    Front Immunol; 2022; 13():1064488. PubMed ID: 36518767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.
    Kim SR; Tone A; Kim RH; Cesari M; Clarke BA; Eiriksson L; Hart TL; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
    Cancer; 2021 Sep; 127(17):3082-3091. PubMed ID: 33983630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
    Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
    Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report.
    Gohda Y; Noguchi R; Horie T; Igari T; Nakamura H; Ohta Y; Yamaguchi K; Ikenoue T; Hatakeyama S; Yusa N; Furukawa Y; Yano H
    BMC Med Genet; 2016 Dec; 17(1):94. PubMed ID: 27938333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The spectrum of Lynch syndrome-associated germ-line mutations in Russia.
    Yanus GA; Akhapkina TA; Iyevleva AG; Kornilov AV; Suspitsin EN; Kuligina ES; Ivantsov AO; Aleksakhina SN; Sokolova TN; Sokolenko AP; Togo AV; Imyanitov EN
    Eur J Med Genet; 2020 Mar; 63(3):103753. PubMed ID: 31491536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch repair deficient-crypts in non-neoplastic colonic mucosa in Lynch syndrome: insights from an illustrative case.
    Shia J; Stadler ZK; Weiser MR; Vakiani E; Mendelsohn R; Markowitz AJ; Shike M; Boland CR; Klimstra DS
    Fam Cancer; 2015 Mar; 14(1):61-8. PubMed ID: 25173403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins.
    Jaballah-Gabteni A; Tounsi H; Kabbage M; Hamdi Y; Elouej S; Ben Ayed I; Medhioub M; Mahmoudi M; Dallali H; Yaiche H; Ben Jemii N; Maaloul A; Mezghani N; Abdelhak S; Hamzaoui L; Azzouz M; Boubaker S
    J Transl Med; 2019 Jun; 17(1):212. PubMed ID: 31248416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lynch Syndrome in Thai Endometrial Cancer Patients.
    Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P
    Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors.
    Ketabi Z; Bartuma K; Bernstein I; Malander S; Grönberg H; Björck E; Holck S; Nilbert M
    Gynecol Oncol; 2011 Jun; 121(3):462-5. PubMed ID: 21388660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline variants screening of MLH1, MSH2, MSH6 and PMS2 genes in 64 Algerian Lynch syndrome families: The first nationwide study.
    Boumehdi AL; Cherbal F; Khider F; Oukkal M; Mahfouf H; Zebboudj F; Maaoui M
    Ann Hum Genet; 2022 Nov; 86(6):328-352. PubMed ID: 36073783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
    Malander S; Rambech E; Kristoffersson U; Halvarsson B; Ridderheim M; Borg A; Nilbert M
    Gynecol Oncol; 2006 May; 101(2):238-43. PubMed ID: 16360201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
    Ponti G; Manfredini M; Tomasi A; Pellacani G
    Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.
    Hodan R; Kingham K; Cotter K; Folkins AK; Kurian AW; Ford JM; Longacre T
    Cancer Med; 2021 Feb; 10(3):1012-1017. PubMed ID: 33369189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical features and management of Lynch syndrome-associated ovarian cancer.
    Ran X; Jing H; Li Z
    J Obstet Gynaecol Res; 2022 Jul; 48(7):1538-1545. PubMed ID: 35478369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.